Pharmaceutical Ireland-headquartered drugmaker Shire, which is defending itself from a $46 billion unsolicited bid from the USA’ AbbVie, says that Judge Stanley Chesler of the US District Court for the District of New Jersey granted Shire’s summary judgment motion in a patent infringement law suit, holding that certain claims of the patents protecting attention-deficit hyperactivity disorder (ADHD) drug Vyvanse (lisdexamfetamine dimesylate) were both infringed and valid. 25 June 2014